Register for email alerts and news feeds:
This journal | BMJ Group
rss
Drug and Therapeutics Bulletin 2009;47:67-70; doi:10.1136/dtb.2009.05.0021
Copyright © 2009 by the BMJ Publishing Group Ltd.

Interferon-gamma release assays and TB diagnosis

Relevant BNF section: 14.4

Worldwide in 2007, there were an estimated 9.27 million new cases of active tuberculosis (TB) and 1.8 million deaths related to the disease.1 However, in most people with TB, the infection is ‘latent’; the underlying cause, Mycobacterium tuberculosis, remains alive but patients are asymptomatic and non-infectious. Latent infection progresses to active disease in around 10% of individuals at some point.2,3 It therefore represents a large reservoir of potential future active cases who, if correctly identified, can be treated with prophylactic anti-tuberculosis chemotherapy before active TB develops.4 Until recently, the only test to indicate the relative risk of an individual having latent TB infection was the tuberculin skin test (TST), but this lacks specificity.3 Here we look at the place of interferon-gamma release assays (IGRAs), a new approach in the diagnosis of TB.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
PubMed
Topic Collections
Bookmark with

Register for email alerts

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Coming soon!

The DTB archive back to 1962, volume 1, issue 1 will soon be available.